KOPS - Das Institutionelle Repositorium der Universität Konstanz

Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequence-optimized genetic adjuvants

Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequence-optimized genetic adjuvants

Zitieren

Dateien zu dieser Ressource

Dateien Größe Format Anzeige

Zu diesem Dokument gibt es keine Dateien.

ÖHLSCHLÄGER, Peter, Michael QUETTING, Gerardo ALVAREZ, Matthias DÜRST, Lutz GISSMANN, Andreas M. KAUFMANN, 2009. Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequence-optimized genetic adjuvants. In: International Journal of Cancer. 125(1), pp. 189-198. ISSN 0020-7136. eISSN 1097-0215

@article{Ohlschlager2009Enhan-1263, title={Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequence-optimized genetic adjuvants}, year={2009}, doi={10.1002/ijc.24333}, number={1}, volume={125}, issn={0020-7136}, journal={International Journal of Cancer}, pages={189--198}, author={Öhlschläger, Peter and Quetting, Michael and Alvarez, Gerardo and Dürst, Matthias and Gissmann, Lutz and Kaufmann, Andreas M.} }

<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:bibo="http://purl.org/ontology/bibo/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > <rdf:Description rdf:about="https://kops.uni-konstanz.de/rdf/resource/123456789/1263"> <bibo:uri rdf:resource="http://kops.uni-konstanz.de/handle/123456789/1263"/> <dcterms:bibliographicCitation>Publ. in: International Journal of Cancer 125 (2009), 1, pp. 189-198</dcterms:bibliographicCitation> <dc:creator>Gissmann, Lutz</dc:creator> <dc:creator>Kaufmann, Andreas M.</dc:creator> <dc:creator>Öhlschläger, Peter</dc:creator> <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2011-03-23T09:07:30Z</dcterms:available> <dc:contributor>Gissmann, Lutz</dc:contributor> <dcterms:rights rdf:resource="http://nbn-resolving.org/urn:nbn:de:bsz:352-20140905103416863-3868037-7"/> <dc:contributor>Alvarez, Gerardo</dc:contributor> <dcterms:title>Enhancement of immunogenicity of a therapeutic cervical cancer DNA-based vaccine by co-application of sequence-optimized genetic adjuvants</dcterms:title> <dc:contributor>Quetting, Michael</dc:contributor> <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2011-03-23T09:07:30Z</dc:date> <dcterms:issued>2009</dcterms:issued> <dc:creator>Alvarez, Gerardo</dc:creator> <dc:contributor>Öhlschläger, Peter</dc:contributor> <dc:creator>Dürst, Matthias</dc:creator> <dcterms:abstract xml:lang="eng">Treatment of patients with cervical cancer by conventional methods (mainly surgery, but also radiotherapy and chemotherapy) results in a significant loss in quality of life. A therapeutic DNA vaccine directed to tumor-specific antigens of the human papilloma virus (HPV) could be an attractive treatment option. We have developed a nontransforming HPV-16 E7-based DNA vaccine containing all putative T cell epitopes (HPV-16 E7SH). DNA vaccines, however, are less immunogenic than protein- or peptide-based vaccines in larger animals and humans. In this study, we have investigated an adjuvant gene support of the HPV-16 E7SH therapeutic cervical cancer vaccine. DNA encoded cytokines (IL-2, IL-12, GM-CSF, IFN-gamma) and the chemokine MIP1-alpha were co-applied either simultaneously or at different time points pre- or post-E7SH vaccination. In addition, sequence-optimized adjuvant genes were compared to wild type genes. Three combinations investigated lead to an enhanced IFN-gamma response of the induced T cells in mice. Interestingly, IFN-gamma secretion of splenocytes did not strictly correlate with tumor response in tumor regression experiments. Gene-encoded MIP-1alpha applied 5 days prior to E7SH-immunization combined with IFN-gamma or IL-12 (3 days) or IL-2 (5 days) postimmunization lead to a significantly enhanced tumor response that was clearly associated with granzyme B secretion and target cells lysis. Our results suggest that a conditioning application and combination with adjuvant genes may be a promising strategy to enhance synergistically immune responses by DNA immunization for the treatment of cervical cancer.</dcterms:abstract> <dc:contributor>Kaufmann, Andreas M.</dc:contributor> <dc:language>eng</dc:language> <dc:rights>deposit-license</dc:rights> <dc:contributor>Dürst, Matthias</dc:contributor> <dc:creator>Quetting, Michael</dc:creator> </rdf:Description> </rdf:RDF>

Das Dokument erscheint in:

KOPS Suche


Stöbern

Mein Benutzerkonto